Vitamin D treatment in allergic skin rashes
Phase 1
Completed
- Conditions
- Health Condition 1: L209- Atopic dermatitis, unspecifiedHealth Condition 2: L209- Atopic dermatitis, unspecified
- Registration Number
- CTRI/2018/07/014727
- Lead Sponsor
- Intramural funds Institute Ethics Committee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 77
Inclusion Criteria
All Children with atopic dermatitis from the age group of 1 year till 14 years attending JIPMER Pediatrics and Dermatology OPD will be recruited and single oral dose Vitamin D3 ( 1,20,000 IU) will be given at enrolment.
Exclusion Criteria
1)Children with chronic underlying disease on immunosuppressive therapy
(Neurological/cardiac/metabolic/respiratory/gastrointestinal)
2)Children with known or suspected immunodeficiency.
3)Children on prolonged antibiotic therapy and Anti tuberculous therapy.
4)Children who are a part of other studies.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EVALUATION OF CLINICAL SEVERITY OF ATOPIC DERMATITIS AND DECREASE IN SCORAD LEVELS OVER A P <br/ ><br>FALL IN IgE ANTIBODY TITRES <br/ ><br>FALL IN ABSOLUTE EOSINOPHIL COUNTSTimepoint: OUTCOMES WILL BE ASSESSED AT THE END OF 4 MONTHS, AFTER GIVING SINGLE DOSE VITAMIN D
- Secondary Outcome Measures
Name Time Method 1)To assess the change in serum 25(OH) D levels after single oral dose ( 1,20,000 IU ) Vitamin D3 supplementation. <br/ ><br>2)To assess the change in absolute eosinophil counts and IgE antibody titres after Vitamin D supplementation. <br/ ><br>3)To assess the reduction in the number of exacerbations. <br/ ><br>Timepoint: 4 months